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1. Introduction 
Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous 
system (CNS) resulting in axon loss and development of disability. (Gabibov et al., 2011) 
Autoantibodies (autoAbs) are one of the major features and crucial mechanisms in MS 
pathogenesis known to illustrate this autoagression. The major component in the 
pathogenesis of MS is primary myelin damage, which is mediated by autoAbs, which 
trigger the release of separate and pathogenically valuable myelin-associated epitopes into 
the bloodstream. These molecules acting as a group of sensitizing factors may provoke the 
immune system and drive disease progression. Being identified at the pre- or early stages or 
the demyelination, such autoAbs dominate during the whole course of the disease. 
Natural catalytic antibodies (catAbs) or natural abzymes today are one of the principal 
effectors of the adaptive immune system. In constructive sense, catAbs are multivalent 
immunoglobulins (Igs), presumably, of IgG and IgM isotypes, endowed with a capacity to 
hydrolyze an antigenic substrate.  
Traditionally, the basic structure of the Ab molecule is essentially Y-shaped, with the two 
tips (Fab-fragments) designed to recognize and bind non-self agents or cells. Moreover, the 
catalytic capacity is also present in Fab-fragments of the molecule. In general, the 
mechanisms of Ab-mediated catalytic action include nucleophilic catalysis, induction of 
conformational strain, coordination with ions, and stabilization of transition states (TS). Ag-
specific or targeted catAbs are preferentially found in the Ig repertoire of patients with a 
broad scope of diseases to act as pathogenically valuable tools. Since the discovery of 
catAbs, a wide spectrum of the disease-related abzymes regardless to their natural history or 
engineering protocols has been described. Moreover, the immune system was shown to 
express an intrinsic drive to generate natural abzymes in different pathological states in 
humans. Among them, proteolytic (Ab-proteases) and DNA-hydrolyzing (DNA-abzymes) 
autoAbs are of a special practical value.  
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And today catAbs can be used as either therapeutic tools or as vehicles for delivering 
therapeutic agents to damaged cells in the human body. Recent applications of abzymes 
have included a broad scope of medical and allied areas, i.e., 
1. the conversion of drugs to their inactive (non-toxic) forms;  
2. the degradation of drugs and harmful substances;  
3. the activation of pro-drugs for targeted chemotherapy;  
4. the inhibition of infectivity;  
5. others. 
The aim of this review is to compare data on the medical applications and implementations 
of disease-associated and engineered abzymes as new tools for treatment of MS, and to 
specifically focus on their potential value for clinical research and for clinical utility and 
public health as well. 
The mechanisms of catAb action include nucleophilic catalysis, induction of conformational 
strain, coordination with metal ions, and stabilization of TS. Only Abs that stabilize the Ag 
TS more than the GS can be catalytic, and such Abs are thus usually identified among those 
that bind tightly to an analogue of the TS of the relevant reaction. Abs would thus provide a 
unique opportunity to combine specific Ag recognition with enzymatic turnover.  
For Ab-proteases, for instance, a typical mechanism of nucleophilic catalysis has been 
established. Since the catalytic efficiency of Ab-proteases derives substantially from the 
ability to recognize the GS with high affinity, proteolytic Abs while demonstrating an 
exclusive targeted specificity can be used to selectively address a wide range of 
metabolically and pathogenically valuable protein targets. 
In case of DNA-abzymes, Ab-induced conformational strain is proposed to activate 
phosphodiester bonds and result in DNA hydrolysis, aided by coordination of bivalent 
cations. As being similar to proteolytic sites, the nuclease activity of DNA-hydrolyzing Abs 
is described to be encoded by germline variable region genes (V-genes).In general, the 
specific nature of the Ab catalysis was demonstrated by the adherence of those reactions to 
the well-known Michaelis-Menten equation, the complete inhibition by a proper hapten 
analogue, and the failure of the Ab to catalyze the hydrolysis of the substrate antagonists. 
During the last 10 years, it has been found that Abs contribute to the degradation of a 
number of autoantigens. These and related “antibody-enzymes”, also termed abzymes, were 
shown to be able to cleave DNA, RNA, carbohydrates, peptides, and proteins Recently, 
abzyme-dependent catalytic degradation of an autoantigen, MBP (myelin basic protein), 
was associated with the course of the neurodegenerative disease MS and its rodent model, 
experimental autoimmune encephalomyelitis (EAE). Autoantibody-mediated degradation 
of MBP was shown to be site specific, with cleavage sites localized to the immunodominant 
epitopes of the protein. These findings were supported by studies from others. Interestingly, 
this reaction was inhibited in vitro by glatiramer acetate (Copaxone), an established 
treatment for MS. (Belogurov et al., 2008) 
There are three groups of autoAbs that are specific for MS: anti-myelin autoAbs (e.g., anti-
MBP, anti-MOG (MOG - myelin oligodendrocyte glycoprotein) and anti-neurofilament 
autoAbs); nonmyelin autoAbs (e.g., anti-HSP autoAbs, among others); and autoAbs 
demonstrating different levels of specificity and functionality (e.g., catalytic autoAbs [i.e., 
antibody proteases]). The latter group of anti-myelin antibody proteases is of particular 
interest in terms of disease monitoring, prognosis and preclinical (pre-early) diagnostics of 
MS. Catalic antbodies are endowed with a capacity to hydroliyze an antigenic substrate. 
This has moved antibodies to the level of physiological functionality by providing such 
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antibodies with the ability to mediate direct catalytic and indirect cytotoxic effects on the 
target. This property is buried in the Fab fragment of the immunoglobulin molecule. 
Antibody protease were found in most autoimmune conditions, particulary in MS, 
accomplishing sequence-specific proteolic cleavage of myelin antigens and controlling the 
degradation of myelin sheath. (Gabibov et al., 2011) 
The worldwide median estimated incidence of MS is 2.5 per 100 000 and prevalence is 
estimated at approximately 1.5 million cases. Usually onset of MS is between age 20 and 40 
years. Men are affected approximately twice as rare as women. (Stuve & Oksenberg, 2006 )  
Autoantibody mediated tissue destruction is among the main features of organ-specific 
autoimmunity. Ample data indicate that a significant portion of MS cases is characterized by 
the presence in the blood of autoantibodies against myelin protein components. Moreover, 
myelin-specific autoantibodies are detected by highresolution microscopic analysis in the 
regions of demyelination plaques in human MS and a MS-like disease of marmosets, 
suggesting their direct contribution to myelin destruction. (Ponomarenko et al., 2006) 
Nonetheless, the mechanisms responsible for the induction of autoantibodies and their 
possible contributions to MS progression are still unknown and are somewhat controversial. 
Also clonal expansion of B cells and T cells, hallmarks of inflammation in the CNS, are 
found in MS. The viral mimicry hypothesis was formulated to explain the initiation of this 
pathology. (Belogurov et al., 2008) But a poor understanding of the etiology of MS has 
complicated the development of effective therapeutics. (Hafler, 2004)  
Despite strong evidence for the contribution of T cell responses to manifestations of 
autoimmunity in the CNS of patients with MS, recent findings encouraged investigators to 
search also for B cell-mediated contributions to the MS pathogenesis. (Klawiter & Cross, 
2007; Nikbin et al., 2007) 
Development of new diagnostics and treating tactics can improve patient life quality and 
decrease MS treatment cost, as in other autoimmune diseases such as type 1 diabetes. (Hahl 
et al., 1998) 
2. Antibodies-mediated demyelination in the pathogenesis of MS 
Antibodies can cause demyelination by several effector mechanisms. One of these is the 
opsonization of myelin for subsequent phagocytosis by macrophages, which has been 
observed in MS and EAE. Serum anti-myelin antibodies raise macrophage phagocytosis, 
and the uptake by macrophages of CNS myelin increases after opsonization with 
complement. Another mechanism of demyelination that involves autoantibodies is through 
activation of the entire complement cascade leading to membrane attack complex (MAC) 
deposition and complement-mediated cytolysis. 
Antibodies with specificity against minor myelin components have also been detected in MS 
patients. MOG is the most interesting candidate B-cell autoantigen in MS. Because of its 
location it is an ideal target for antibody-mediated demyelination. Anti-MOG antibodies are 
indeed able to cause myelin destruction in EAE models, while other antibodies against 
major myelin proteins such as MBP or PLP, which are both not located on the myelin 
surface, do not cause myelin destruction on their own. Anti-MOG Abs mediate a 
characteristic vesicular transformation of compact myelin in acutely demyelinated lesions 
that also has been documented in human MS lesions strongly suggesting a role of anti-MOG 
Abs in MS. The B-cell response to MOG is enhanced in MS also supporting the pathogenic 
importance of anti-MOG Abs. Interestingly, the presence of serum anti-MOG antibodies, 
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with or without anti-MBP antibodies, in patients presenting with an initial clinical event 
suggestive of central nervous system demyelination and evidence of multifocal lesions on 
MRI studies, is predictive of subsequent clinical events that establish the diagnosis of clini-
cally definitive MS. However, the presence of anti-MOG antibodies in patients with 
nondemyelinating diseases of the CNS, as well as in a substantial number of healthy 
individuals, has raised important questions about the role of these antibodies in MS, and 
these need to be addressed in future studies. 
2.1 Catalysis 
The neurodegenerative model of MS is based on the proposition of a primary lesion in 
myelin followed by myelin breakdown and the release of myelin-compartmentalized 
proteins, particularly MBP. This is followed by the generation of MBP-derived peptides that 
become the main sensitizers of T cells. (Hafler, 2004) The hypothesis that interactions 
between MBP and T cells must occur at sites other than the myelin membrane has been 
challenged by recent physicochemical studies demonstrating that myelin can become 
structurally unstable secondary to specific posttranslational modifications of MBP structure. 
This was shown to result in the increased surface exposure and susceptibility to proteolysis 
of MBP 83–92. (Husted, 2006) The close association between the proteolytic sensitivity of 
MBP and the pattern of posttranslational modifications of the molecule may represent one 
of the key regulatory mechanisms in epitope generation (Lolli et al., 2005). Proteolysis may 
proceed by any of four distinct pathways that may exert a concerted attack on the MBP 
molecule, although the mechanisms responsible for the activation and regulation of these 
potential activities are not known. Thus, epitope generation may occur via:  
1. autocatalytic cleavage of the MBP molecule (D’Souza et al., 2005);  
2. protease digestion (D’Souza et al., 2006);  
3. autoantibody-mediated site-specific cleavage (Ponomarenko et al., 2006); 
4. Abdependent oxidative pathway (Wentworth et al., 2001).  
The last mechanism, which has been demonstrated in a number of autoimmune pathologies, 
remains unproven for MS (Wentworth et al., 2001). These pathways are characterized by 
dramatic differences in reaction velocities and in cleavage site specificity. Obviously the 
rates of enzymatic reactions are several times higher than those for autocatalysis and 
Abenzymes (abzymes), perhaps making this pathway the major player in epitope 
generation. In the case of abzymes, the large excess of the biocatalyst, its high specificity, 
and its close compartmentalization with the MBP substrate shown in demyelinating lesions 
are suggestive of its likely effectiveness in vivo. (Ponomarenko et al., 2006; Genain et al., 
1999) 
Today, the advent of antibody catalysis has demonstrated that antibodies can be 
programmed to perform complex cell biochemistry, and thus a logical question arises: does 
the original (nature-gifted) potential for catalysis relate to antibody function? In the sense of 
the question, it is very interesting to consider the evolution of antibodies, while generally 
accepting that natural enzymes are primitive molecules compared with antibodies, and that 
antibodies arose just after the birth of enzymes. 
A great deal of evidence has been also adduced to support the medical concept of the living 
soul of abzymes and their significance for utilizing broader autoantibodies properties in the 
formation of pathogenic patterns and clinical settings at different autoimmune and other 
conditions. Moreover, the medical concept of abzymes was tested in two ways, clinically 
and experimentally, i.e., on human and animal models. The progress achieved earlier in 
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designing artificial abzymes initiated the study of biological activities of natural catalytic 
autoantibodies and their involvement in pathogenesis of major clinical disorders, i.e., 
evoked the onset of the era of medical abzymology. (Suchkov et al., 2001; Zhou et al., 2002; 
Tellier, 2002; Nathan, 2002; Kozyr et al., 1998) 
Medical abzymology has made a great contribution to the development of general 
autoimmunity theory: it has put the antibody as a functional entity and as the key brick of the 
theory to the level of physiological functionality by providing such antibody with the ability to 
catalyze and mediate direct and independent cytotoxic effect on cellular and molecular 
targets. 
3. Major antigenic targets of the anti-myelin autoAbs 
There are extensive information on a significant portion of MS cases, characterized by the 
presence of autoantibodies against myelin protein components in serum of patients with 
MS. (Chamczuk et al., 2002; Reindl et al., 1999) Although the mechanism of the 
autoantibody role in MS pathogenesis is unknown , autoantibodies to MBP and MOG were 
proposed as biomarkers for clinical prognosis of MS. (Berger et al., 2003) Similar 
immunoglobulins were also found in mice with induced EAE, which is an animal model of 
MS. (Fritz et al., 1983)  
3.1 Myelin basic protein 
Myelin basic protein is by far the best studied myelin component in MS. It is the second 
most abundant myelin protein (approximately 30-40%) after PLP. There are five MBP 
isoforms with 14-21.5 kDa molecular weights in mammals that result from differential 
splicing of 11 axons within the Golli-MBP locus. The highly basic MBP is positioned at the 
intracellular surface of myelin membranes and via interactions with acidic lipid moieties is 
involved in maintaining the structure of compact myelin. The most abundant 18.5 kDa 
isoform (170 amino acid length) has been used in most immunological studies.  
Different from MOG, and PLP (proteolipid protein), MBP is found in both central and 
peripheral myelin, and MBP transcripts have also been demonstrated in peripheral 
lymphoid organs such as lymph nodes and thymus. 
 
 
Fig. 1. MBP sites of proteolysis by different enzymes-proteases and Abs-proteases and as a 
result of spontaneous autocatalytic hydrolysis. The sequence of the encephalitogenic peptide 
81–103 is shown in red. Abbrevations: GelB (Gelatinase B), MMP-3 (matrix 
mettaloproteinase-3), CatD (Cathepsin D), ACat (Autocatalytic cleavage), Abz (Abzyme), LP 
(Lysosomal Proteases), Tryp4 (Trypsin 4). 
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3.2 Proteolipid protein 
Proteolipid protein (PLP) is the most abundant protein in CNS compact myelin (about 50%), 
highly hydrophobic and evolutionarily conserved across species. There are two main tran-
scripts, the full-length 276 amino acid isoform and DM-20, an isoform that lacks 35 amino 
acids and is mainly expressed in brain and spinal cord prior to myelination, but also in 
peripheral lymphoid organs such as the thymus, where full-length PLP is barely found. 
Interestingly, the major encephalittogenic and immunodominant PLP peptide (139-154) is 
contained in full-length PLP but not in DM-20. This observation is thought to account for the 
encephalittogenicity and immunodominance of the PLP (139-154) peptide, since it is 
essentially not available for thymic negative selection and consequently a high precursor 
frequency of PLP (139-154)-specific T cells has been observed even in naive unprimed 
animals. 
3.3 Myelin oligodendrocyte glycoprotein 
Myelin oligodendrocyte glycoprotein, a 218 amino acid trancemembrane glycoprotein of the 
IG superfamily, is much less abundant (0.01 - 0.05%) than MBP and PLP, and also different 
from the two major myelin proteins in being located not in compact myelin but exposed on 
the outermost surface of the oligodendrocyte membrane. Because of this “strategic” location, 
it is directly accessible to antibodies and believed to be particularly relevant as a target for 
both cellular and humoral immune responses in MS. MOG, is expressed relatively late 
during myelination and is only found in the brain/spinal cord and the retina but not in 
peripheral nerve. Furthermore, MOG expression is either completely or almost completely 
lacking in peripheral lymphoid tissues, although MOG transcripts have been seen in 
nonhuman primate peripheral nerve and a few samples of human tonsils and thymus. 
4. Nonmyelin autoAbs 
4.1 DNA abzymes and antibody proteases 
Catalytic antibodies are endowed with a capacity to hydrolyze an antigenic substrate. (Paul 
S. 1998; Paul et al., 2005; Friboulet et al., 1999) This has moved antibodies to the level of 
physiological functionality by providing such antibodies with the ability to mediate direct 
catalytic and indirect cytotoxic effects on the targets. This property is buried in the Fab 
fragment of the immunoglobulin molecule. Antibody proteases (antibodies with proteolytic 
activity) were found in most autoimmune conditions, particularly in MS, accomplishing 
sequence-specific proteolytic cleavage of the myelin antigens and controlling the 
degradation of the myelin sheath. The levels of proteolytic activity of the antibody proteases 
revealed significant correlations with the clinical activity of the course over the disease, and 
thus with the disability of the patients. The most attractive point is that, in contrast to 
canonical proteases, for antibody proteases, there is an extra set of cleavage sites in the 
targeted autoantigens (for sequence-specific proteolytic cleavage) focused predominantly at 
the immunodominant sites. (Gabibov et al., 2002) 
Physiological interaction of autoAb with a living cell is mediated by Fc fragment (Wilkinson 
et al., 2001). DNA-abzymes are able to realize both cytotoxicity mechanisms-complement-
dependent cell lysis and K-cell-mediated lysis. (Fishelson et al., 2001) Fab fragment is not 
involved in these reactions. This fundamentally distinguishes Ab-mediated classical and 
DNA-mediated mechanisms of cytotoxicity due to direct involvement of Fab fragment into 
the catalytic attack on the target cell genome. Catalytic and cytotoxic activities of DNA-
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abzymes are closely related. This allows to assume on a hypothesis on a new mechanism of 
the contribution of autoAbs into the pathogenesis of autoimmune disorders. Such 
mechanism acts independently of complement and cytotoxic T cells; it requires a 
catalytically active Fab fragment but ignores Fc fragment whose structure is deprived of 
even buried resources providing direct cytotoxic effect. (Ponomarenko et al., 2000) 
Two different mechanisms of DNA-abzymes cytotoxic potential utilization are established-
by means of direct cytotoxic effect on a target cell involving the catalytically active Fab 
fragment and by means of apoptosis due to high affinity of DNA-binding autoAbs for 
membrane receptors providing the cell with features of possible target. Cross-reactive with 
such such cells, DNA-abzymes can provoke their degradation resulting in the development 
of different syndromal manifestations: lupus nephritis in glomerule endothelium cross-
reactivity, articular syndrome in synovial cross-reactivity, extracardial manifestations and 
MCS progression in CM cross-reactivity. (Rekvig et al., February 2004; Raz et al., 1993) 
Cross-reactivity of DNA-binding autoAbs with glutamate receptors accumulating at neural 
cells is of a special interest. Such autoAbs with catalytic and cytotoxic activities can initiate 
neural cells apoptosis providing the possibility for the development of CNS autoimmune 
degenerative disorders (Kotzin et al., 2001). The penetration of DNA-binding autoAbs (and 
DNA-abzymes) into a cell results in activation of cytotoxicity mechanisms, apoptosis 
induction, etc. 
4.2 Molecular mechanisms of the involvement of DNA-abzymes in the development of 
different autoimmunity conditions and pathogenesis of autoimmune disorders 
One antigen may generate up to 102-104 different antibody molecules, a number that may 
further increase by somatic mutagenesis. Therefore, it seems feasible that different DNA-
binding and other non-catalytic antibodies, as well as antibodies with catalytic activities can 
be synthesized in the course of immune response, either directed against the substrate or as 
antiidiotypic antibodies to enzymes hydrolyzing nucleic substrates. It is certainly difficult to 
predict the clinical significance of these catalytic activities, but it is likely that they modify 
the pathogenesis or clinical process of these autoimmune diseases. 
The interest to catalytic (i.e., DNA-hydrolyzing activity) of the autoantibodies is kept on 
growing up and is strongly supported by the new data including those illustrating cytotoxic 
activities of the biocatalysts and evidence that abzyme-mediated cytotoxic effects observed 
in human SLE (system lupus erythematosis) and mouse SLE-like syndromes are caspase-
dependent and thus apoptosis-related. 
5. Prediction of MS 
The use of assays for Abs to MBP and MOG for diagnostic and prognostic purposes in 
patients with a clinically isolated syndrome (CIS), a frequent precursor to clinically definite 
MS (CDMS), has yielded conflicting results. One study showed that the presence of myelin 
Abs in the sera of CIS patients was predictive of a shorter time course to the development of 
CDMS. (Tomassini et al., 2007) Others, however, indicated that positive tests had no 
prognostic value for progression to CDMS. (Kuhle et al., 2007)  
Symbols indicate OD450 values for Abs from individual subjects within each EDSS category 
for specific MBP peptides or intact MBP and MOG proteins. Lines indicate the relation 
between EDSS value and the binding activity of specific peptides/proteins: MBP 81-103 (R2 
0.332; p 0.005), MBP 130-156 (R2 0.381; p 0.011), MBP 146-170 (R2 0.310; p 0.033), intact MBP 
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(R2 0.458; p 0.005), intact MOG (R2 0.052; p 0.001), and control Trx carrier protein (R2 0.055; 
p 0.376) 
 
 
Fig. 2. Correlation of the EDSS of MS patients with the levels of autoantibodies to MBP 
fragments.  
The latter results are in keeping with our demonstration that the binding activities of Abs to 
intact MBP and MOG proteins were indistinguishable for patients with MS and other 
neurological diseases (OND). In addition, a screen of MBP peptides showed that the 
reactivity of Abs from patients with MS and OND could be distinguished only by their 
differential binding to MBP 43–68 and MBP 146–170. Follow-up studies of patients with MS 
using assays based on the use of these fragments will be needed to determine whether it 
provides an improved prognostic tool for patients with CIS. 
Interestingly, the parameters of Ab binding associated with disease progression were 
different from those with potential prognostic value. Disease severity, as determined by 
Expanded disability status scale (EDSS), correlated with level of autoantibodies to intact 
MBP and MOG proteins as well as MBP fragments 81–103, 130–156 and 146–170. These 
findings are in keeping with the demonstrated correlations between levels of anti-MOG and 
anti-MBP Abs and inflammatory signs revealed by MRI and cerebrospinal fluid analyses. 
(Kuhle et al., 2007) 
5.1 Diagnostic protocol 
The appearance of Ab-proteases at the pre-early (preclinical) stages of demyelination to 
illustrate myelin degradation has been documented. 
The results we had obtained would allow for approaching to a novel generation of 
diagnostic technologies based on the protocols of clinical and preclinical diagnostics to 
exploit Ab-proteases and their sequence-specificity. 
The protocols would include: 
1. isolation of individual Ab-proteases from sera of MS patients or persons to be at risks 
for suspicious MS (e.g., the relatives); 
2. quantification of the proteolytic activity of Ab-proteases; 
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3. determination of sequence-specificity of the individual Ab-proteases towards MBP as 
the whole molecule and separate peptides (epitope-bearing) fragmented from the 
molecule as well; 
4. verification of the diagnosis and prediction for the future. 
A phenomenon of the pre-clinical formation of the abzyme-based armamentarium and Ab-
proteases, in particular, would be interpreted as a portion of the proper immune response of 
the body to the environmental and other shifts. So, a selection of the mode of action for 
proteolytic antibodies would depend on the metabolic motivation occurring at a particular 
stage of the disease. Of great interest would be driving motivation to control the mode of 
action at the preclinical stages. 
The occurrence of antibody proteases among healthy individuals is due to the development 
of the pre-early immune imbalances and formation of the preclinical conditions. So, when 
bursts of the antibody-associated proteolytic activity or the tendency for the latter were 
evident, the pre-early stages preceding formation of CIS and the exacerbation of the disease 
could be predicted, even with no observable clinical manifestations. There was definite 
correlation between the interval before CIS and autoAb (including antibody proteases) 
status. The occurrence of antibody proteases and the degree of their activity were signifi-
cantly associated with symptomatology/severity of CIS and clinical course of the disease. 
5.2 Sequence specificity and clinical implementation 
Sequence specificity of Ab-proteases is the capacity to distinguish or not distinguish 
between particular epitopes in the MBP molecule. Serum anti-MBP auto-Abs obtained from 
MS patients exhibited sequence-specific proteolytic cleavage of the MBP molecule. Such 
antibody proteases revealed significant correlations with different manifestations of MS (i.e., 
progressive and/or remittance phases of the disease), with Expanded Disability Status Scale 
scores and thus with scales of demyelination and, moreover, with the degree of disability of 
MS patients. For instance, anti-MBP antibody proteases that are able to recognize 43-68 and 
146-170 amino acid sequences within the MBP molecule are predominantly more typical of 
MS patients, but not of patients with neurodegenerative diseases other than MS. In MS 
patients with low disease activity (in remission), a family of antibody proteases has been 
detected with low proteolytic activity that predominantly targets 43-68 and 146-170 amino 
acid sequences within MBP. Progression of disability in MS patients is accompanied by the 
bursts of anti-MBP antibody-associated sequence-specific proteolytic activity. Moreover, 
signs of a trend in the specificity of the activity were found (i.e., specificity of the sequence 
recognition from 43-68 and 146-170 amino acid sites with low affinity to 81-103 and 82-98 
amino acid sites, demonstrating that high-affinity indices are recognized by anti-MBP 
antibody proteases). (Ponomarenko et al., 2006) 
5.3 Perspectives in the application of catalytic antibodies for clinical medicine 
More than a hundred of abzyme-catalyzed reactions have been described. Catalytic efficacy 
of some abzymes is comparable with those of enzymes, but the specificity of abzymes is 
even higher. The practical relevance of abzymes is due to the unique feature drastically 
distinguishing them from other biocatalysts, i.e., abzymes could be produced for the 
catalysis of not only all the reactions occuring in the living systems but also be designed for 
the development of principally new catalysts with no natural counterparts. (Gabibov et al., 
2002; Zhou et al., 2002) In this sense, we can anticipate that manmade catalytic antibodies 
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will have considerable practical potential in many different medical applications, i.e., would 
form the frame of medical abzymology. 
Medical abzymology as a novel trend in medical immunology and enzymology, and a new 
avenue in the clinical practice appears to demonstrate a revolutionary growth today. The 
antibody catalysis as itself and regardless to a defined field of medical application appears 
to stress a new area of medical research and a novel field of medical application that 
provoke considerable interest for medical investigators and clinical practitioners. (Suchkov 
et al., 2006; Suchkov et al., 2001) 
Autoimmune diseases actually represent a challenging frontier in contemporary medical 
research and clinical practice, and, thus, in areas overlapped with medical abzymology. The 
proper relation of clinical autoimmunity to the generation of natural catalytic antibody 
response is absolutely evident, and, in general terms, the phenomenon of autoantibody 
catalysis can potentially be applied to isolate efficient catalytic domains directed against 
autoimmune epitopes pathogenically and clinically relevant. This can be done by exposing 
the autoimmune repertoire to identify autoantigens or their mimicking counterparts capable 
of recruiting the germ line genes encoding the catalytic site. 
6. Conclusion 
The prospects for progress in developing novel approaches for the diagnosis and treatment 
of MS have been greatly encouraged by several observations. These include:  
1. the identification of a major immunogenic region in MBP, peptide 82–98;  
2. the demonstration that both B and T cell responses to MBP are focused on this region, 
particular for patients who express HLA-DR2;  
3. clinical studies suggesting that patients treated with MBP peptide 82–98 can be made 
tolerant to the protein in association with delayed disease progression or reduced disease 
activity over time. Autoantibody mediated tissue destruction is among the main features 
of organ-specific autoimmunity. Since the original discovery of catalytic antibodies, ample 
data established their contribution to pathological effects in disease as well as their 
possible biomedical applications. The practical relevance of abzymes is due to the unique 
characteristic distinguishing them from other biocatalysts: abzymes could be produced for 
the catalysis of almost all reactions occurring in living systems and catalyzed by 
appropriate enzymes. Abzymes may also be designed for the development of 
fundamentally new catalysts without natural analogues. The proved possibility to set a 
cell on secretion of engineering biocatalysts is intensively discussed. Serum level of 
proteolytic Abs may provide a clinically important predictive biomarker for 
demyelination in MS patients and formulating prognosis of the disease. The serum levels 
of the Ab-mediated catalytic activity as prognostic criteria could also differentiate MS 
patients with probably favorable or severe disease course or outcome, and outcome 
criteria are now being designed to assess the overall impact of MS as dependent variables 
for clinical studies. Ultimately, analysis of autoAb-mediated MBP degradation may 
provide a supplementary clinical and laboratory tool for assessing the disease progression 
and disability of MS patients. The possibility of forced stimulation of B-cells to produce 
proteolytic Abs with a given design is also intensively discussed. Such technology could 
be widely applied to treat and prevent socially relevant autoimmune disorders.  
Achievements in medical abzymology could be a promising basis to design new medicines. 
The most dynamic trend is related to the synthesis of catalytic Abs that are able to destroy 
www.intechopen.com
Antibody-Proteases in the Pathogenesis of Autoimmune  
Demyelination and Monitoring Patients with Multiple Sclerosis 
 
487 
circulating drugs before initiating toxic effects on nervous system and other tissues. 
Catalytic Abs directly affecting the physiologic reconstruction of tissues and organ systems 
with complex architectonics including neuroglia are of special value. Neurology is estimated 
as an interesting area for abzyme application since Abs can be used for the induction of 
remyelination and the restoration of previously lost glia functions in MS.  
List of abbreviations: 
MS - Multiple sclerosis 
CNS - central nervous system 
autoAbs – Autoantibodies 
catAbs - catalytic antibodies 
Igs – immunoglobulins 
TS - transition states 
MBP - myelin basic protein 
EAE - experimental autoimmune encephalomyelitis 
MOG - myelin oligodendrocyte glycoprotein 
HSP – heat shock protein 
MAC - membrane attack complex 
PLP - Proteolipid protein 
SLE - system lupus erythematosis 
CIS - clinically isolated syndrome 
CDMS - clinically definite multiple sclerosis 
EDSS - Expanded disability status scale 
MRI – magnetic resonance imaging 
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